Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer - Concepedia

Concepedia

Publication | Open Access

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

DOI Full Paper Access

816

Citations

30

References

2009

Year

David Cunningham, Ian Chau, Deborah Stocken, Juan W. Valle, David B. Smith, William P. Steward, Peter Harper, Janet Dunn, Catrin Tudur Smith, Julia West,

Journal of Clinical Oncology

Abstract

On the basis of our trial and the meta-analysis, GEM-CAP should be considered as one of the standard first-line options in locally advanced and metastatic pancreatic cancer.

References

	Year	Citations

Page 1